CJC-1295 (No DAC)
$39.99
In stockCJC-1295 is an investigational synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a hormone that signals the pituitary gland to release growth hormone. Research has examined its ability to increase growth hormone and insulin-like growth factor 1 (IGF-1), a hormone involved in growth and tissue metabolism.
| SKU | RC-ST-CJC1295N-5MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 5 mg |
| Size | 3 mL Vial |
| Reported Result | See matching batch report |
| Stock | In stock |
| Documentation Status | Client-supplied report available |
Product Description
CJC-1295 is an investigational synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a hormone that signals the pituitary gland to release growth hormone. Research has examined its ability to increase growth hormone and insulin-like growth factor 1 (IGF-1), a hormone involved in growth and tissue metabolism.
What research has shown for CJC-1295 with DAC:
Increased growth hormone: Two randomized, placebo-controlled trials in healthy adults found dose-dependent increases in average growth hormone levels lasting at least six days after a single administration.
Increased IGF-1: The same trials reported elevated IGF-1 levels lasting approximately 9–11 days after a single administration.
Preserved growth hormone pulses: A separate human study found that growth hormone continued to be released in pulses while baseline and average levels increased. Pulse frequency and magnitude were not significantly changed.
Storage and handling: Keep unopened lyophilized material sealed, protected from light and moisture, and stored according to the manufacturer label and current COA. Product-specific stability after reconstitution must be supported by manufacturer data; avoid publishing a universal reconstituted shelf life.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|---|---|---|---|---|
| CND5/2025-12-18-B | 99.295%; 99.307% | Jan 5, 2026 | Janoshik | Client-supplied report | View COA |
.png)